Skip to main content
HCPCS J0589 · Level II · Part B drug

J0589: daxibotulinumtoxina-lanm (Daxxify), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0589

Billing unit
1 UNIT
Inj daxibotulinumtoxina-lanm
ASP payment limit
$3.252
October 2026; +6.0% vs July 2026
Practitioner MUE
300
MAI 3
OPPS status
SI G
APC 0703
NCCI exposure
no PTP pairs
Coverage articles
10
35 states

TL;DR

HCPCS J0589 is the Level II code for Injection, daxibotulinumtoxina-lanm, 1 unit, billed per 1 UNIT. The Medicare Part B ASP payment limit for October 2026 is $3.252 per billing unit, up 6.0% from July 2026. The practitioner MUE allows up to 300 units per date of service (MAI 3), so a full 300-unit day is $975.60 at the current limit. Under OPPS it carries status indicator G in APC 0703. J0589 is billed in units of 1 UNIT; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Daxxify by Revance Therapeutics, Inc. 10 Medicare coverage articles list the code across 29 states plus DC and 5 territories, including A57114.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0589 at $3.252 per 1 UNIT for October 2026, derived from manufacturer average sales price plus 6%, compared with $3.067 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J0589
QuarterPayment limitPerCoinsurance
October 2026$3.2521 UNIT20%
July 2026$3.0671 UNIT—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J0589. Report the NDC in the claim's drug segment and bill the number of J0589 units that equals the quantity administered divided by 1 UNIT; the last column gives units per full package.

NDCs that crosswalk to J0589
NDCDrug nameLabelerPackage sizeBilling units / package
72960-0112-01DaxxifyRevance Therapeutics, Inc.1 × 1100

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J0589. For practitioners the limit is 300 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J0589 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services3003 Date of Service Edit: ClinicalClinical: Data
Facility outpatient hospital3003 Date of Service Edit: ClinicalClinical: Data
DME supplier03 Date of Service Edit: ClinicalClinical: Data

MUE for J0589 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0589 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0589 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0589 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

10 current Medicare Administrative Contractor articles list J0589 in their HCPCS tables, covering 35 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J0589
ArticleTitleContractor(s)StatesRelated LCD
A57114Billing and Coding: Trigger Point InjectionsFirst Coast Service Options, Inc.FL PR VIL33912
A57185Billing and Coding: Botulinum Toxin InjectionsNoridian Healthcare Solutions, LLCAS CA CNMI GU HI NVL35170
A57186Billing and Coding: Botulinum Toxin InjectionsNoridian Healthcare Solutions, LLCAZ MT ND SD UT WYL35172
A57715Billing and Coding: Botulinum ToxinsFirst Coast Service Options, Inc.FL PR VIL33274
A57751Billing and Coding: Trigger Point InjectionsNovitas Solutions, Inc.DC DE MD NJ PAL35010
A58423Billing and Coding: Botulinum ToxinsNovitas Solutions, Inc.DC DE MD NJ PAL38809, L40016
A59707Billing and Coding: Botulinum Toxin InjectionsWellpoint FederalCT IL MN NY WIL39832
A59714Billing and Coding: Botulinum Toxin InjectionsPalmetto GBANC SC VA WVL39836
A59726Billing and Coding: Botulinum Toxins InjectionsCGS Administrators, LLCKY OHL39857
A59809Billing and Coding: Botulinum Toxin InjectionsWisconsin Physicians Service Insurance CorporationIA KS MO NEL39909, L40381

Diagnoses Medicare contractors cover for J0589

8 billing and coding articles attach a covered diagnosis list to J0589: 11 distinct ICD-10-CM codes in all. The 11 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 11 covered ICD-10-CM codes for J0589
ICD-10-CMDescription (FY2027)Articles covering
G24.3Spasmodic torticollis8 of 8
G24.02Drug induced acute dystonia6 of 8
G24.09Other drug induced dystonia6 of 8
G24.1Genetic torsion dystonia6 of 8
G24.2Idiopathic nonfamilial dystonia6 of 8
G80.3Athetoid cerebral palsy6 of 8
M43.6Torticollis6 of 8
M47.812Spondylosis without myelopathy or radiculopathy, cervical region6 of 8
M47.892Other spondylosis, cervical region6 of 8
M54.2Cervicalgia6 of 8
Q68.0Congenital deformity of sternocleidomastoid muscle6 of 8

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J0589 are counted here: a group whose instructions name J0589, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J0589, by article
ArticleContractorGroups that applyCovered codes for J0589Full list
A57114First Coast Service Options, Inc.groups are written for 20552, 20553—On LCD L33912
A57185Noridian Healthcare Solutions, LLCgroup 5 applies to J058911On LCD L35170
A57186Noridian Healthcare Solutions, LLCgroup 5 applies to J058911On LCD L35172
A57715First Coast Service Options, Inc.group 5 applies to J05891On LCD L33274
A57751Novitas Solutions, Inc.groups are written for 20552, 20553—On LCD L35010
A58423Novitas Solutions, Inc.group 5 applies to J05891On LCD L38809
A59707Wellpoint Federalgroup 5 applies to J058911On LCD L39832
A59714Palmetto GBAgroup 5 applies to J058911On LCD L39836
A59726CGS Administrators, LLCgroup 5 applies to J058911On LCD L39857
A59809Wisconsin Physicians Service Insurance Corporationgroup 5 applies to J058911On LCD L39909

2 more articles list J0589 but write their diagnosis groups for other procedure codes in the same article; there the diagnosis has to fit the group written for the procedure billed with the drug.

Local coverage policies that list J0589

10 active Local Coverage Determinations list J0589 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

  • Trigger Point Injections (L35010) · Novitas Solutions, Inc.
  • LCD L38809: Botulinum Toxins · Novitas Solutions, Inc.
  • Botulinum Toxin Injections, LCD L39909 · Wisconsin Physicians Service Insurance Corporation
  • L33274 Botulinum Toxins · First Coast Service Options, Inc.
  • L33912 Trigger Point Injections · First Coast Service Options, Inc.
  • L35170 Botulinum Toxin Injections · Noridian Healthcare Solutions, LLC
  • L35172 Botulinum Toxin Injections · Noridian Healthcare Solutions, LLC
  • L39832 Botulinum Toxin Injections · Wellpoint Federal
  • L39836 Botulinum Toxin Injections · Palmetto GBA
  • L39857 Botulinum Toxin Injections · CGS Administrators, LLC

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0589 carries status indicator G and is assigned to APC 0703, with a published national unadjusted payment of $3.252. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0589 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $3.25 per 1 UNIT, paid only when the drug is furnished integral to a covered surgical procedure. Pass-through status expires *.

Common denials for J0589 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

Prior authorization in Original Medicare

  • Ambulatory surgical centers in the CMS prior authorization demonstration: January 19, 2026 in California, Florida, Georgia, Maryland, New York, Pennsylvania and Tennessee; February 16, 2026 in Arizona, Ohio and Texas; requests are voluntary, and claims without one go to pre-payment review. CMS service group: Botulinum toxin injections.

Medicare Advantage plans run their own prior authorization lists. See this code on the Medicare prior authorization list.

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0589

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0589

What does HCPCS code J0589 describe?

J0589 is defined by CMS as "Injection, daxibotulinumtoxina-lanm, 1 unit". Each billing unit represents 1 UNIT, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0589 a CPT code?

No. J0589 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as daxibotulinumtoxina-lanm (Daxxify); CPT codes are five-character codes maintained by the AMA. On a Part B claim J0589 reports the drug itself in 1 unit units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0589 in October 2026?

The ASP-based payment limit is $3.252 per 1 UNIT, with 20% beneficiary coinsurance. The July 2026 limit was $3.067. Commercial payers use their own fee schedules.

How many units of J0589 can be billed per day?

The practitioner Medically Unlikely Edit is 300 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Data" as the rationale.

Which NDCs map to J0589?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Daxxify (Revance Therapeutics, Inc.). For example NDC 72960-0112-01 (package size 1) equals 100 billing units of J0589.

Does J0589 have NCCI bundling edits?

No active practitioner PTP pairs list J0589 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J0589?

10 current Billing and Coding Articles in the Medicare Coverage Database list J0589, covering 29 states plus DC and 5 territories: A57114 (Billing and Coding: Trigger Point Injections); A57185 (Billing and Coding: Botulinum Toxin Injections); A57186 (Billing and Coding: Botulinum Toxin Injections).

What diagnosis codes support J0589?

8 Medicare billing and coding articles list 11 covered ICD-10-CM codes for J0589 between them, for example G24.3 (Spasmodic torticollis); G24.02 (Drug induced acute dystonia); G24.09 (Other drug induced dystonia); G24.1 (Genetic torsion dystonia); G24.2 (Idiopathic nonfamilial dystonia). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it. 2 more articles tie their diagnosis groups to other procedure codes they list rather than to J0589.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.